After a 1.5-Year Selloff, It’s time to Get Long Gilead Sciences, Inc. (GILD) Gilead Sciences, Inc. (GILD) is a research-based biopharmaceutical company. Through research and development they discover, develop, and commercialize innovative medicines designed to …
Continue readingGILD
Biotech and Healthcare stocks are down a couple percent today after an epic bounce following the surprise outcome of the presidential election. A few weeks ago we detailed defined risk trade ideas in the S&P …
Continue readingWith the election results decided, and the market not down the 5% it was as indicated by the futures last night, you may be forgiven for thinking that we basically have market status quo from yesterday’s …
Continue reading
Shares of Gilead (GILD) are down 40% from their all time highs made in July 2015. You know the reasons, increased scrutiny on drug pricing, moderating sales growth resulting from price declines for their blockbuster Hepatitis …
Continue reading
We’re not getting to hear much policy discussion in this strange presidential election cycle but one topic that sometimes gets through is healthcare. A hot button issue over the past year on the Democratic presidential …
Continue reading
Event: Gilead (GILD) reports their Q2 results after the close, the options market is implying about a 4.5% one day post earnings move tomorrow, which is inline with their 4 quarter one day average move …
Continue reading
Less than a two weeks ago we expressed a bullish view for healthcare stocks to play a bit of catch up with the S&P 500 (SPX) as it approached its prior all time highs, choosing …
Continue reading
When market participants lack confidence in the underpinnings of the investment environment they quickly turn to technical analysis as their main trading input (there are some traditionalists with a long timer horizon that still view …
Continue reading
In case you missed it, global equities have been volatile over the last month: the German Dax trading in 9% range from prior peak to trough last week, and now back within 1.5% from the …
Continue reading
Biotech stocks have in focus of late, as they appear to be ground zero for concerns of an equity bubble as a result of strong performance, non-stop m&a activity, recent volatility and valuation concerns among …
Continue reading